Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 10/20 | 0.78 |
| ▸ | NOS3 | P29474 | 2/20 | 0.71 |
| ▸ | NOS2 | P35228 | 2/20 | 0.71 |
| ▸ | USP2 | O75604 | 1/20 | 0.58 |
| ▸ | CASP7 | P55210 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | BLM | P54132 | 1/20 | 0.56 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | PAH | P00439 | 1/20 | 0.48 |
| ▸ | SOST | Q9BQB4 | 1/20 | 0.47 |
| ▸ | FPGS | Q05932 | 2/20 | 0.46 |
| ▸ | GART | P22102 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31561469 | 0.88 | NOS1 (0.69) | NOS1NOS3NOS2USP2CASP7 | |
| SCHEMBL4649233 | 0.84 | NOS1 (0.72) | NOS1NOS3NOS2USP2CASP7 | |
| SCHEMBL4649231 | 0.84 | NOS1 (0.72) | NOS1NOS3NOS2USP2CASP7 | |
| SCHEMBL9248337 | 0.84 | NOS1 (0.72) | NOS1NOS3NOS2USP2CASP7 | |
| SCHEMBL10615701 | 0.83 | NOS1 (0.71) | NOS1NOS3NOS2USP2CASP7 | |
| SCHEMBL10852056 | 0.81 | NOS1 (0.75) | NOS1NOS3NOS2USP2CASP7 | |
| SCHEMBL10849648 | 0.80 | NOS1 (0.66) | NOS1NOS3NOS2USP2CASP7 | |
| SCHEMBL10854897 | 0.79 | NOS1 (0.83) | NOS1NOS3NOS2USP2CASP7 | |
| SCHEMBL584982 | 0.78 | NOS1 (0.64) | NOS1NOS3NOS2USP2CASP7 | |
| SCHEMBL16564267 | 0.78 | NOS1 (0.56) | NOS1NOS3NOS2USP2CASP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119925601-A | Application of tetrahydrobiopterin pathway as target in anti-QDPR deletion type tumor | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | 2025-05-06 | — | — | CN | claimed |
| WO-2024084421-A1 | TREATMENT OF VASCULAR DISEASES ASSOCIATED WITH GENETIC VARIATIONS IN ACTA2 | QRGENETICS LTD. (IL) | 2024-04-25 | — | — | WO | claimed |
| WO-2019175328-A1 | BH4PATHWAYACTIVATIONANDUSETHEREOFFORTREATINGCANCER | IMBA - INSTITUT FÜR MOLEKULARE BIOTECHNOLOGIE GMBH (AT) | 2019-09-19 | — | — | WO | claimed |
| US-20080221111-A1 | Roflumilast and sepiapterin; (6R)-L-erythro-5,6,7,8-tetrahydrobiopterin; prevention, treatment of respiratory diseases | NYCOMED GMBH (DE) | 2008-09-11 | — | — | US | claimed |
| EP-1940392-A2 | COMBINATION OF THE PDE4 INHIBITOR AND A TETRAHYDROBIOPTERIN DERIVATIVE | Nycomed GmbH (DE) | 2008-07-09 | — | — | EP | claimed |
| WO-2006120176-A2 | COMBINATION OF THE PDE4 INHIBITOR ROFLUMILAST AND A TETRAHYDROBIOPTERIN DERIVATIVE | NYCOMED GMBH (DE) | 2006-11-16 | — | — | WO | claimed |
| WO-2005018620-A2 | USE OF NITRIC OXIDE SYNTHASE (NOS) COFACTOR FOR THE TREATMENT OF SEXUAL DYSFUNCTION | CELL CENTER COLOGNE GMBH (DE) | 2005-03-03 | — | — | WO | claimed |
| US-20250255873-A1 | RESTORING FUNCTION OF SPECIFIC MUTATIONS AFFECTING THE ACTIN DYNAMIC BY ADMINISTRATION OF SAPROPTERIN | QRGENETICS LTD. (IL) | 2025-08-14 | — | — | US | disclosed |
| WO-2024084421-A1 | TREATMENT OF VASCULAR DISEASES ASSOCIATED WITH GENETIC VARIATIONS IN ACTA2 | QRGENETICS LTD. (IL) | 2024-04-25 | — | — | WO | disclosed |
| EP-2813509-B1 | 3,4,4a,10b-tetrahydro-1h-thiopyrano-[4,3-c]isoquinoline derivatives | ASTRAZENECA AB (SE) | 2017-02-01 | — | — | EP | disclosed |
| US-9492451-B2 | Stable compositions of tetrahydrobiopterin | DIPHARMA S.A. (CH) | 2016-11-15 | — | — | US | disclosed |
| US-20160136169-A1 | SYSTEMS AND METHODS FOR DELIVERY OF TETRAHYDROBIOPTERIN AND RELATED COMPOUNDS | TRANSDERMAL BIOTECHNOLOGY, INC. (US) | 2016-05-19 | — | — | US | disclosed |
| US-20160108049-A1 | Novel Phthalazinone-Pyrrolopyrimidinecarboxamide Derivatives | ASTRAZENECA AB (SE) | 2016-04-21 | — | — | US | disclosed |
| US-6410535-B1 | SUBSTITUTED TETRAHYDROPTERIN COMPOUNDS INCREASE NITROUS OXIDE PRODUCTION AND SUPPRESS PRODUCTION OF ACTIVE OXYGEN SPECIES TO IMPROVE DISORDERS OF VASCULAR ENDOTHELIAL CELLS | SUNTORY LIMITED (JP) | 2002-06-25 | — | — | US | disclosed |
| EP-1200437-A1 | METHOD FOR PRODUCING BY STEREOSPECIFIC HYDRATION TETRAHYDROPTERINS AND OPTICALLY PURE DERIVATIVES, IN PARTICULAR TETRAHYDROFOLIC ACID AND ITS OPTICALLY PURE DERIVATIVES | EPROVA AG Forschungsinstitut (CH) | 2002-05-02 | — | — | EP | disclosed |
| US-6288067-B1 | ADMINISTERING 5,6,7,8-BIOPTERIN DERIVATIVE; SIDE EFFECT REDUCTION | SUNTORY LIMITED (JP) | 2001-09-11 | — | — | US | disclosed |
| WO-2001004120-A1 | METHOD FOR PRODUCING BY STEREOSPECIFIC HYDRATION TETRAHYDROPTERINS AND OPTICALLY PURE DERIVATIVES, IN PARTICULAR TETRAHYDROFOLIC ACID AND ITS OPTICALLY PURE DERIVATIVES | EPROVA AG (CH) | 2001-01-18 | — | — | WO | disclosed |
| EP-1004308-A1 | PREVENTIVES OR REMEDIES FOR DRUG-INDUCED RENAL DISTURBANCE | SUNTORY LIMITED (JP) | 2000-05-31 | — | — | EP | disclosed |
| EP-0983765-A1 | PREVENTIVES OR REMEDIES FOR DISEASES IN ASSOCIATION WITH VASCULAR FUNCTIONAL ANOMALY RELATING TO INSULIN RESISTANCE | SUNTORY LIMITED (JP) | 2000-03-08 | — | — | EP | disclosed |
| EP-0908182-A1 | PREVENTIVES OR REMEDIES FOR DISEASES INDUCED BY HYPOFUNCTION OF NITRIC OXIDE SYNTHASE (NOS) | SUNTORY LIMITED (JP) | 1999-04-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250255873-A1 | RESTORING FUNCTION OF SPECIFIC MUTATIONS AFFECTING THE ACTIN DYNAMIC BY ADMINISTRATION OF SAPROPTERIN | ACTR2, ACTB, ACTR3 | NOS1 2695/4885NOS3 3271/4885NOS2 1672/4885 |
| US-20160136169-A1 | SYSTEMS AND METHODS FOR DELIVERY OF TETRAHYDROBIOPTERIN AND RELATED COMPOUNDS | LRAT, LTC4S, CETP | NOS1 594/4885NOS3 347/4885NOS2 424/4885 |
| US-20080221111-A1 | Roflumilast and sepiapterin; (6R)-L-erythro-5,6,7,8-tetrahydrobiopterin; prevention, treatment of respiratory diseases | SPR, PAH, QDPR | NOS1 264/4885NOS3 173/4885NOS2 293/4885 |
| US-20160108049-A1 | Novel Phthalazinone-Pyrrolopyrimidinecarboxamide Derivatives | PDE4A, PDE4B, PDE5A | NOS1 1013/4885NOS3 1238/4885NOS2 1355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.